Seres Therapeutics (MCRB) Form 3 Seres Therapeutics / Marcus Chapman ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Chapman Marcus

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

200 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/18/2019

3. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	03/24/2025	Common Stock	25,000	15.77	D
Stock Option (Right to Buy)	(2)	01/31/2026	Common Stock	12,500	26.2	D
Stock Option (Right to Buy)	(3)	01/25/2027	Common Stock	10,000	9.89	D
Stock Option (Right to Buy)	(4)	01/29/2028	Common Stock	18,000	10.42	D
Restricted Stock Units	(5)	(6)	Common Stock	12,000	(7)	D
Stock Option (Right to Buy)	(8)	01/31/2029	Common Stock	23,000	6.38	D

Explanation of Responses:

1. The option is fully vested and exercisable.

2. The option has vested as to 25% of the shares on February 1, 2017. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter.

3. The option has vested as to 25% of the shares on January 26, 2018. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter.

4. The option has vested as to 25% of the shares on January 30, 2019. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter.

5. These restricted stock units will vest in full on November 1, 2019.

6. Not applicable.

7. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

8. This option will vest as to 25% of the shares on February 1, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney Principal Financial and Accounting Officer

	/s/ Thomas J. DesRosier, Attorney-in-fact for Marcus Chapman	04/24/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.